Last reviewed · How we verify
PalinGen Flow Amniotic Tissue Allograft
PalinGen Flow Amniotic Tissue Allograft is a Biologic drug developed by Amnio Technology, LLC. It is currently in Phase 2 development.
At a glance
| Generic name | PalinGen Flow Amniotic Tissue Allograft |
|---|---|
| Sponsor | Amnio Technology, LLC |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PalinGen Flow Amniotic Tissue Allograft CI brief — competitive landscape report
- PalinGen Flow Amniotic Tissue Allograft updates RSS · CI watch RSS
- Amnio Technology, LLC portfolio CI
Frequently asked questions about PalinGen Flow Amniotic Tissue Allograft
What is PalinGen Flow Amniotic Tissue Allograft?
PalinGen Flow Amniotic Tissue Allograft is a Biologic drug developed by Amnio Technology, LLC.
Who makes PalinGen Flow Amniotic Tissue Allograft?
PalinGen Flow Amniotic Tissue Allograft is developed by Amnio Technology, LLC (see full Amnio Technology, LLC pipeline at /company/amnio-technology-llc).
What development phase is PalinGen Flow Amniotic Tissue Allograft in?
PalinGen Flow Amniotic Tissue Allograft is in Phase 2.